BioLineRx And Hemispherian To Present GLIX1 Data At EANO 2026; Stock Up
(RTTNews) - diseases, together with Hemispherian AS, announced that encouraging preclinical data of GLIX1 will be presented at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) taking place September 24-27, 2026, in Rome, Italy.
One abstract has been selected for oral presentation on September 25, 2026, highlighting GLIX's efficacy in orthotopic?glioblastoma models. A second abstract will detail the design of the ongoing Phase 1/2a clinical trial.
GLIX1 is an oral small molecule that activates TET2, a key regulator of the DNA damage response. In preclinical studies, GLIX1 demonstrated potent anti-tumor activity across multiple glioblastoma models, including temozolomide-resistant patient derived xenografts.
The compound achieved strong central nervous system penetration, with brain exposures reaching 68-85% of plasma levels. These findings support its potential as a novel therapy for glioblastoma, one of the most aggressive and treatment-resistant cancers.
In two orthotopic glioblastoma xenograft models, GLIX1 produced dose-dependent tumor growth inhibition and survival benefits at all tested doses, with greater efficacy at higher doses. Antitumor activity was observed even at the lowest dose tested, reinforcing the drug's therapeutic promise.
The ongoing first-in-human Phase 1/2a trial is actively enrolling patients. The open-label study uses a BOIN design to guide dose escalation across up to five dose levels in 30 patients, the study will evaluate GLIX1's safety, tolerability, and preliminary efficacy. The program represents a significant step forward in addressing the urgent need for more effective glioblastoma treatments.
BLRX has traded between $2.15 and $4.56 over the past year. The stock closed Wednesday's trading at $2.55, down 0.39%. In pre-market trading the stock is at $2.80, up 9.80%.
